Monitor for protocol finalization and trial initiation, which could catalyze partnership interest and revaluation. Positive trial results could lead to accelerated approval with substantial commercial upside in a niche but high-need indication.
ONCY drugs
ONCY drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 27 $0.9700entry
- T+1 · 7mo ago −7.22%α −6.73% · $0.9000
- T+5 · 7mo ago −4.12%α −4.52% · $0.9300
- T+20 · 6mo ago −16.46%α −21.42% · $0.8103
- T+60 · 4mo ago −14.68%α −19.46% · $0.8276
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Oncolytics Biotech announced alignment with the FDA on a randomized controlled pivotal trial design for pelareorep in metastatic squamous cell carcinoma of the anal canal (SCAC), a rare cancer with no approved therapies post-first-line treatment. The study leverages strong prior data showing improved duration of response and survival versus standard of care.
Key Facts
- FDA alignment achieved on pivotal randomized controlled trial for pelareorep in metastatic SCAC
- Study targets post-standard-of-care population with no FDA-approved options
- Prior data showed 15.5 vs 9.5 month median duration of response and 82% vs 45.7% 12-month survival vs standard of care
- Trial design may support both accelerated and full approval
- Pelareorep already has Fast Track designation for colorectal and pancreatic cancers
Financial Impact
Significant potential value creation if trial succeeds, given unmet need in rare cancer and potential for dual approval pathway
Risk Factors
- Clinical trial execution risk in a rare cancer population
- Regulatory requirements may evolve despite current alignment
- Dependence on successful enrollment and funding for trial completion
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001129928-26-000026 |
| Document: scacfdaalignment.htm | 0001129928-26-000026 |
| Document: 0001129928-26-000026-index-headers.html | 0001129928-26-000026 |
| Document: 0001129928-26-000026-index.html | 0001129928-26-000026 |
| Document: 0001129928-26-000026.txt | 0001129928-26-000026 |
Track record
32 reports on ONCY
3 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +10.53% at T+5 after the Apr 6, 2026 report. 7 of 11 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 3/10 Entry $0.3700 Now $0.3400 −8.11% settles Dec 14
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
- Nov 11, 20265d ago Press Release Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
- Nov 9, 20267d ago 8-K Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
- Oct 27, 202620d ago 8-K Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
- Oct 27, 202620d ago Press Release Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.4986 Now $0.3400 −31.81% settles Nov 17
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers